MAG and neuropathy: The present results, especially nerve excitability changes and clinically meaningful improvement in currently less treatable or untreatable conditions represented by anti-MAG neuropathy and CMT1a support the construction of a large randomized controlled trial to assess the potential benefit of treating demyelinating neuropathies with hdPB.